MBX Biosciences (MBX) Share-based Compensation (2023 - 2026)

MBX Biosciences has reported Share-based Compensation for 4 years, with the latest figure at $40.7 million in Q1 2026.

• Quarterly Share-based Compensation rose 2113.16% year-over-year to $40.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.7 million (up 872.75% YoY) and the FY2025 annual result came in at $25.2 million, up 41.57% from the prior year.
• Share-based Compensation improved to $40.7 million in Q1 2026 per MBX's latest filing, from $2.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $40.7 million in Q1 2026 and troughed at $227000.0 in Q3 2023.
• A 4-year average of $8.6 million and a median of $1.6 million in 2024 frame the typical range for Share-based Compensation.
• The widest YoY moves for Share-based Compensation: up 6637.8% in 2025, down 13.31% in 2025.
• Over 4 years, Share-based Compensation stood at $1.0 million in 2023, then jumped by 46.17% to $1.5 million in 2024, then soared by 78.49% to $2.7 million in 2025, then surged by 1432.38% to $40.7 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $40.7 million, $2.7 million, and $22.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.